RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Teuto or Verdemed?Generic Epidiolex isn't the only path forward but it will likely be the most lucrative out of the gate. Once rescheduling happens the entire US synthetic market opens up, in addition to increased clinical investment. I think their only true compeitor currently is Brains Bioceutical, if I'm wrong please correct. We've kicked the can down the road so many times but it finally feels like our time is now. We also can't forget about Remidose, which I think was a very savvy deal. It's a much simpler tech but don't forget that Syqe was acquired by Philip Morris for $600M last year. Again, after rescheduling, I truly believe that this train won't stop - I have ~600K shares @ $0.115 so I have to believe it lol.